The role of the cylooxygenase pathway in nociception and pain.
Cycloxygenase (COX) pathways have long been targeted for the treatment of inflammatory pain, initially through the use of NSAIDs. With the demonstration of two major COX isoforms, COX-1 and COX-2, involved in the production of prostanoids, but with different distribution and regulation, selective COX-2 inhibitors have been developed. This review covers factors influencing COX enzyme activity, the role of their products in the development and maintenance of pain and discusses recent safety concerns of COX-2 inhibitors.
Bingham
Sharon
S
Neurology and Gastrointestinal CEDD, GlaxoSmithKline, Coldharbour Road, Harlow, Essex CM19 5AW, UK. Sharon.Bingham@gsk.com
Beswick
Paul J
PJ
Blum
David E
DE
Gray
Norman M
NM
Chessell
Iain P
IP
D001665:Binding Sites; D051545:Cyclooxygenase 1 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000737:chemistry / Q000502:physiology*; D052246:Cyclooxygenase 2 Inhibitors / Q000737:chemistry* / Q000592:standards / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D015394:Molecular Structure; D009619:Nociceptors / Q000502:physiology; D010146:Pain / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology; D020033:Protein Isoforms; D017434:Protein Structure, Tertiary; D015398:Signal Transduction
D052246:Cyclooxygenase 2 Inhibitors; D020033:Protein Isoforms; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2